[BostonCard]

What is tricky though is that this med is given by IV, and seems most useful if given early in patients without severe disease. The logistical issues this raises will limit the ultimate effectiveness of this medication in limiting the pandemic.

Do they need to be hospitalized and for how long? If so, then it seems like if we're going to treat people "early," before they have severe symptoms, we're going to have to hospitalize and treat a lot of people.

You could have patients treated in an outpatient infusion center, but obviously that would need to be tested.

The other result that was reported today (by Gilead) was that a five-day treatment course had similar outcomes to a ten-day treatment course which would make the drug more viable for use in an outpatient setting.

I’m sure Gilead will be testing remdisivir in an outpatient study, with an outcome of the need for hospitalization.

Lastly, there will probably be a move to make the drug available as a subcutaneous auto-injector.  It shouldn’t be too difficult to show that the pharmacokinetics of the SC administration can be made similar to IV.

BC

[BostonCard]

What is tricky though is that this med is given by IV, and seems most useful if given early in patients without severe disease. The logistical issues this raises will limit the ultimate effectiveness of this medication in limiting the pandemic.

Do they need to be hospitalized and for how long? If so, then it seems like if we're going to treat people "early," before they have severe symptoms, we're going to have to hospitalize and treat a lot of people.

You could have patients treated in an outpatient infusion center, but obviously that would need to be tested.

The other result that was reported today (by Gilead) was that a five-day treatment course had similar outcomes to a ten-day treatment course which would make the drug more viable for use in an outpatient setting.

I’m sure Gilead will be testing remdisivir in an outpatient study, with an outcome of the need for hospitalization.

Lastly, there will probably be a move to make the drug available as a subcutaneous auto-injector.  It shouldn’t be too difficult to show that the pharmacokinetics of the SC administration can be made similar to IV.

BC